These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27143666)

  • 1. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
    Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
    Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
    Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
    N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
    Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
    PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
    Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
    Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
    J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Maganda BA; Minzi OM; Kamuhabwa AA; Ngasala B; Sasi PG
    Malar J; 2014 May; 13():205. PubMed ID: 24885714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
    Tchaparian E; Sambol NC; Arinaitwe E; McCormack SA; Bigira V; Wanzira H; Muhindo M; Creek DJ; Sukumar N; Blessborn D; Tappero JW; Kakuru A; Bergqvist Y; Aweeka FT; Parikh S
    J Infect Dis; 2016 Oct; 214(8):1243-51. PubMed ID: 27471317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
    Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
    Whalen ME; Kajubi R; Goodwin J; Orukan F; Colt M; Huang L; Richards K; Wang K; Li F; Mwebaza N; Aweeka FT; Parikh S
    Clin Infect Dis; 2023 Feb; 76(3):443-452. PubMed ID: 36130191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
    Nyunt MM; Nguyen VK; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Mwima MW; Achan J; Aweeka F; Parikh S; Mwebaza N
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1274-82. PubMed ID: 26666942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.
    Denoeud-Ndam L; Dicko A; Baudin E; Guindo O; Grandesso F; Sagara I; Lasry E; Palma PP; Parra AM; Stepniewska K; Djimde AA; Barnes KI; Doumbo OK; Etard JF
    BMC Infect Dis; 2015 Jun; 15():228. PubMed ID: 26068100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
    Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
    Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
    Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
    BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.